Risk of Cutaneous T Cell Lymphoma with Psoriasis Biologic Therapies
Abstract Background The risk of developing cutaneous T cell lymphoma (CTCL) in patients using psoriasis biologics has not been well characterized. The goals of this review were to investigate the incidence of CTCL in patients with psoriasis receiving biologic therapy in clinical trials and psoriasis...
Main Authors: | Mitchell S. Davis, Riley K. Spencer, Chandler E. Johnson, Kareem G. Elhage, Joy Q. Jin, Marwa Hakimi, Tina Bhutani, Wilson Liao |
---|---|
Format: | Article |
Language: | English |
Published: |
Adis, Springer Healthcare
2023-12-01
|
Series: | Dermatology and Therapy |
Subjects: | |
Online Access: | https://doi.org/10.1007/s13555-023-01074-z |
Similar Items
-
Compositional Alteration of Gut Microbiota in Psoriasis Treated with IL-23 and IL-17 Inhibitors
by: Yu-Huei Huang, et al.
Published: (2023-02-01) -
Interleukin-17 vs. Interleukin-23 Inhibitors in Pustular and Erythrodermic Psoriasis: A Retrospective, Multicentre Cohort Study
by: Gianluca Avallone, et al.
Published: (2023-02-01) -
A systematic review of active comparator controlled clinical trials in patients with moderate-to-severe psoriasis
by: Daniel J. No, et al.
Published: (2018-07-01) -
Living with Psoriasis Vulgaris and Multi-Treatment Failure: A Patient and Dermatologist Perspective
by: Riley K. Spencer, et al.
Published: (2023-03-01) -
Levels of IL-23/IL-17 Axis in Plasma and Gingival Tissue of Periodontitis Patients According to the New Classification
by: Ruth Rodríguez-Montaño, et al.
Published: (2022-08-01)